Accretive Wealth Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Accretive Wealth Partners’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-63,150	Closed	-$170K	–	139
2024 Q1	$170K	Buy	+63,150	New	+$392K	0.08%	135

Other funds holding EIGR

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Accretive Wealth Partners's EIGR Position: Q2 2024 in Review

Accretive Wealth Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 63,150 shares — an estimated $170K sold.

Accretive Wealth Partners first reported a position in EIGR in Q1 2024 and held it in 1 quarter. The position peaked at $170K in Q1 2024. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.

Accretive Wealth Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
Accretive Wealth Partners sold 63,150 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $170K.
Accretive Wealth Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2024 and held it in 1 quarter.
Accretive Wealth Partners's Eiger BioPharmaceuticals, Inc. position peaked at $170K in Q1 2024.
2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.

Based on Accretive Wealth Partners's 13F filing for Q2 2024, filed 5 Aug 2024.